Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Instagram Outage Disrupts Thousands of U.S. Users 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
DEVON, Pa., July 28, 2017 -- It is with great sadness that Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) mourns the death of Director Cynthia A. Rask, M.D.
“All of the Zynerba family are mourning the loss of Cynthia, our friend and Director,” said Armando Anido, Chairman and Chief Executive Officer of Zynerba. “Cynthia was a wonderful person, an important contributor to our board, and a strong believer and supporter of the work we are doing at Zynerba. With the rest of our team, I offer my most sincere sympathies to the Rask family during this difficult time.”
Dr. Rask, an accomplished pharmaceutical and biotechnology veteran, joined the Zynerba Board of Directors in August 2015, where she was instrumental in developing Zynerba’s focus in epilepsy. She trained in Internal Medicine and Neurology at the University of Rochester and was board-certified in Neurology and in Clinical Neurophysiology. During her time at FDA, she served as division director for the Division of Clinical Evaluation and Pharmacology/Toxicology in the Office of Cellular, Tissue and Gene Therapies (OCTGT) Dr. Rask earned her degrees at Cornell University and the University of Minnesota Medical School.
Zynerba Contact William Roberts, Vice President, Investor Relations and Corporate Communications Zynerba Pharmaceuticals 484.581.7489 [email protected]
